The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy

References

• Landre T, Justeau G, Assié JB, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022;71(3):719–726. doi:10.1007/s00262-021-03031-1
   PubMed Web of Science ®Google Scholar
• Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting; 2013:359–364.
   Google Scholar
• Moore AR, Rosenberg SC, McCormick F, Malek S. Author Correction: RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(12):902. doi:10.1038/s41573-020-0089-1
   PubMed Web of Science ®Google Scholar
• Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS G12C somatic mutations across race, sex, and cancer type. N Engl J Med. 2021;384(2):185–187. doi:10.1056/NEJMc2030638
   PubMed Web of Science ®Google Scholar
• Loong HH, Du N, Cheng C, et al. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Translat Lung Cancer Res. 2020;9(5):1759–1769. doi:10.21037/tlcr-20-455
   PubMed Web of Science ®Google Scholar
• Arbour KC, Jordan E, Kim HR, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res. 2018;24(2):334–340. doi:10.1158/1078-0432.CCR-17-1841
   PubMed Web of Science ®Google Scholar
• Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J Med Chem. 2020;63(13):6679–6693. doi:10.1021/acs.jmedchem.9b02052
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371–2381. doi:10.1056/NEJMoa2103695
   PubMed Web of Science ®Google Scholar
• Hong D, Bang Y, Barlesi F, et al. 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Ann Oncol. 2020;31:S812. doi:10.1016/j.annonc.2020.08.1571
   Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54–71. doi:10.1158/2159-8290.CD-19-1167
   PubMed Web of Science ®Google Scholar
• Briere DM, Li S, Calinisan A, et al. The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol Cancer Ther. 2021;20(6):975–985. doi:10.1158/1535-7163.MCT-20-0462
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Liu Q, et al. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacol Ther. 2022;229:108050. doi:10.1016/j.pharmthera.2021.108050
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–551. doi:10.1038/nature12796
   PubMed Web of Science ®Google Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–1217. doi:10.1056/NEJMoa1917239
   PubMed Web of Science ®Google Scholar
• Dy GK, Govindan R, Velcheti V, et al. Abstract CT008: long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100. Cancer Res. 2022;82(12_Supplement):CT008–CT008. doi:10.1158/1538-7445.AM2022-CT008
   Web of Science ®Google Scholar
• J ML. Presented at European Society for Medical Oncology (ESMO) 2022 Annual Meeting; September 9–13; 2022; Paris, France.
   Google Scholar
• Riely GJ, Ou SI, Rybkin I, et al. 99O_PR KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thoracic Oncol. 2021;16(4):S751–S752. doi:10.1016/S1556-0864(21)01941-9
   Web of Science ®Google Scholar
• Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non–Small-Cell lung cancer harboring a KRAS G12C mutation. N Engl J Med. 2022;387(2):120–131. doi:10.1056/NEJMoa2204619
   PubMed Web of Science ®Google Scholar
• Luo J, Ostrem J, Pellini B, et al. Overcoming KRAS-mutant lung cancer. Am Soc Clinl Oncol Educ Book. 2022;41:1–11.
   Google Scholar
• Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40. doi:10.1038/nrd2781
   PubMed Web of Science ®Google Scholar
• Zhang XC, Wang J, Shao GG, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019;10(1):1772. doi:10.1038/s41467-019-09762-1
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Herbst R, Lopes G, Kowalski D, et al. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042. Ann Oncol. 2019;30:xi63–xi64. doi:10.1093/annonc/mdz453.001
   Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328. doi:10.1093/annonc/mdz167
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Rodriguez-Abreu D, Felip E, et al. KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. Ann Oncol. 2019;30:xi64–xi65. doi:10.1093/annonc/mdz453.002
   Google Scholar
• West H, Cappuzzo F, Reck M, et al. 1265P IMpower150: a post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. Ann Oncol. 2020;31:S817–S818. doi:10.1016/j.annonc.2020.08.1579
   Web of Science ®Google Scholar
• Nagasaka M, Azmi AS. Clinical progress of KRAS-targeted therapies: what next? Future Med Chem. 2022;14(15):1107–1110. doi:10.4155/fmc-2022-0128
   PubMed Web of Science ®Google Scholar
• Désage AL, Léonce C, Swalduz A, Ortiz-Cuaran S. Targeting KRAS mutant in non-small cell lung cancer: novel insights into therapeutic strategies. Front Oncol. 2022;12:796832. doi:10.3389/fonc.2022.796832
   PubMed Web of Science ®Google Scholar
• LoRusso PM. SY20-KRAS anniversary session: novel mechanisms for targeting KRAS-The clinical successes and challenges of drugging KRAS. American Association for Cancer Research Annual Meeting 2022 Itinerary Planner Home; 2022.
   Google Scholar
• Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–223. doi:10.1038/s41586-019-1694-1
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Shokat KM. Targeting KRAS G12C with Covalent inhibitors. Annual Rev Cancer Biol. 2022;6:49–64. doi:10.1146/annurev-cancerbio-041621-012549
   Google Scholar